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Abstract	
	
Schizophrenia	 symptoms	 consist	 of	 positive	 symptoms	 and	 negative	 symptoms.	
Schizophrenia	consists	of	three	phases,	that	are	acute	phase,	the	stabilization	phase	and	
stable	phase.	Therapeutic	 target	based	on	 the	phase	and	 severity	of	 illness.	 PANSS‐EC	
test	 (Positive	and	Negative	Syndrome	Scale‐Excited	Component)	 is	an	 instrument	 that	
can	be	used	 to	evaluate	 the	 therapeutic	efficacy.	Pharmacologic	 therapy	 is	used	 in	 the	
form	of	 antipsychotic	drugs	which	divided	 into	 two	groups,	 typical	 antipsychotics	 (ex:	
haloperidol)	and	atypical	antipsychotics	(ex.	Risperidone).	The	aim	of	this	study	was	to	
investigate	 the	 effectiveness	 and	 cost‐	 effectiveness	 of	 between	 haloperidol	 and	
risperidone	on	the	acute	phase	of	schizophrenia	based	on	PANSS‐EC	value.	
The	 study	 was	 observational	 method,	 pretest‐posttest	 design,	 non‐randomised,	
prospective,	and	open‐label.	The	total	sample	 is	40	schizophrenia	patients	 in	 intensive	
care	 hospitalization.	 The	 effectiveness	 therapy	 was	 done	 by	 PANSS‐EC.	 Cost‐
effectiveness	analysis	was	done	using	cost‐effectiveness	diagram.	
From	 Mann‐Whitney	 test	 showed	 that	 there	 was	 no	 difference	 of	 effectiveness	
when	using	haloperidol	combination	or	 risperidone	combination	 in	 the	acute	phase	of	
schizophrenia	 patients	 based	 on	 PANSS	 –	 EC,	 but	 the	 results	 of	 cost‐effectiveness	
analysis	showed	haloperidol	combination	therapy	better	than	risperidone	combination	
therapy	on	the	acute	phase	of	schizophrenia	patients.	
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1. Introduction	
 
One	 of	 mental	 health	 disorders	 are	 still	 relatively	 high	 in	 Indonesia	 is	
Schizophrenia.	The	 insidence	of	schizophrenia	 in	Indonesia	estimated	three	to	 five	per	
1000	 population	 (Hawari,	 2007),	 it	 means	 about	 1	 million	 Indonesian	 people	 with	
schizophrenia	(Arif,	2006).	Schizophrenia	is	a	severe	mental	disorder	characterized	by	a	
distinctive	and	fundamental	distortions	in	thinking	and	perception	that	is	accompanied	
by	 the	 blunt	 affect	 or	 unnatural	 (Tandon	 et	 al.,	 2013).	 Schizophrenia	 symptoms	 are	
positive	symptoms,	negative	symptoms,	disorganized,	decreased	cognitive	function	and	
mood	 disorders.	 Based	 on	 American	 Psychiatric	 Association	 (APA),	 schizophrenia	
disease	 consists	 of	 three	phases,	 there	 are	 acute	 phase,	 stabilization	phase	 and	 stable	
phase	 (Reverger,	 2012),	 so	 the	 goal	 of	 therapy	will	 vary	 depending	 on	 the	 phase	 and	
severity	of	illness	(Melatiani	et	al,	2013).		
	
Pharmacological	 treatment	 of	 schizophrenia	 were	 divided	 into	 two	 groups:	
Typical	 antipsychotic	 (first	 generation)	 such	 as	 Haloperidol,	 Chlorpromazine,	
amitripthyline,	etc;	and	Atypical	antipsychotic	(second	generation)	such	as	risperidone,	
clozapine,	olanzapine,	 and	etc	 (Michal&Iva,	2015).	The	 types	of	drugs	most	commonly	
used	to	is	the	typical	antipsychotic	haloperidol	(Reverger,	2012)	and	single	therapy	that	
often	 used	 in	 Indonesia	 is	 risperidone	 from	 atypical	 antipsychotic	 (Jarut	 et	 al,	 2013).	
Research	 on	 the	 effectiveness	 of	 schizophrenia	 treatment	 is	 still	 being	 developed	
because	 there	 are	 no	 therapies	 that	 are	 truly	 effective	 until	 today.	 Selection	 of	
appropriate	 therapy	 in	 the	 acute	 phase	 of	 schizophrenia	 is	 very	 important,	 because	 it	
can	 determine	 the	 prognosis	 of	 the	 course	 of	 schizophrenia.	 PANSS‐EC	 (Positive	 and	
Negative	 Syndrome	 Scale‐Excited	 Component)	 	 is	 a	 simple	 and	 intuitif	 tool	 that	 can	
evaluate	of	positive	symptoms	and	negative	symptom	in	acute	phase	of	schizophrenia.		
	
Schizophrenia	 treatment	 costs	 will	 give	 negative	 impact	 for	 patients	 and	 their	
families.	 The	 overall	 cost	 of	 schizophrenia	 in	 the	US	 (2002)	 is	 estimated	 to	 be	 $	 62.7	
billion,	with	$	22.7	billion	excess	direct	health	care	costs	($	7.0	billion	outpatient,	$	5.0	
billion	drug,	 $	 2.8	 billion	hospitalization	 cost,	 $	 8.0	 billion	 long‐term	 care	 )	 (Wu	 et	 al,	
2005).	Sinaga	(2007)	mentions	that	the	economic	burden	to	be	borne	by	persons	with	
schizophrenia	and	 their	 families	 turned	out	 to	be	quite	 large,	because	50%	of	persons	
with	schizophrenia	are	unable	to	work,	the	cost	of	treatment	and	care	must	be	take	for	a	
long‐term,	 as	well	 as	 the	 time	 consumed	 for	 family	members	 caring	 for	 persons	with	
schizophrenia	were	affecting	the	economic	burden	of	the	family.		
	
The	treatment	of	schizophrenia	requires	monitoring	of	the	effectiveness,	safety	of	
treatment,	 and	 cost‐effectiveness	 because	 it	 need	 long	 term	 therapy.	 The	 aim	 of	 this	
study	was	to	investigate	the	effectiveness	and	cost‐	effectiveness	of	between	haloperidol	
combination	 therapy	 and	 risperidone	 combination	 therapy	 in	 the	 acute	 phase	 of	
schizophrenia	 based	 on	 PANSS‐EC	 score.	 We	 hope	 the	 results	 of	 this	 study	 will	
contribute	 to	 the	 government's	 policy	 decisions	 in	 the	 selection	 of	 appropriate	
procedures,	effective,	and	efficient	for	schizophrenia	treatment.	
	
2. Material	and	Methods		
	
The	 study	 was	 observational	 method,	 pretest‐posttest	 design,	 non‐randomised,	
prospective,	and	open‐label.	The	total	sample	 is	40	schizophrenia	patients	 in	 intensive	
care	 hospitalization,	 Grhasia	 Psychiatric	 Hospital	 of	 Yogyakarta.	 This	 study	 inclusion	
criteria	was	all	patients	diagnosed	with	schizophrenia	with	psychotic	symptoms	in	the	
acute	phas.	The	exclusion	criteria	was	 schizophrenic	patients	with	 congenital	physical	
defects,	impaired	verbal	function,	and	organic	mental	disorders.	
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The	 effectiveness	 therapy	 was	 done	 by	 PANSS‐EC	 (Positive	 and	 Negative	
Syndrome	 Scale‐Excited	 Component).	 PANSS‐EC	 is	 an	 instrument	 used	 to	 assess	 the	
improvement	 in	 the	 state	 of	 schizophrenic	 patients	 in	 the	 acute	 phase.	 PANSS‐EC	
consists	of	 five	main	 items,	excitement,	 tension,	hostility,	uncooperativeness,	and	poor	
impulse	 control.	 The	 5	 items	 from	 the	 PANSS‐EC	 are	 rated	 from	 1	 (not	 present)	 to	 7	
(extremely	severe);	scores	range	from	5	to	35;	mean	scores	≥	20	clinically	correspond	to	
severe	agitation	(Lindenmayer	et	al,	2008). Schizophrenia	patients	the	acute	phase	will	
be	moved	 into	 the	stable	phase	 if	 the	PANSS‐EC	score	≤	15.	PANSS‐EC	assessment	has	
been	done	at	the	beginning	(pre‐test)	and	end	of	treatment(post‐test).		
	
Cost‐effectiveness	 analysis	 was	 done	 using	 cost‐effectiveness	 diagram.	 	 Cost‐
effectiveness	diagram	can	determine	whether	or	not	to	do	AEB.	Before	doing	AEB,	some	
calculation	phase	to	be	done,	there	are:	
 Identify	the	level	of	drugs	effectiveness	from	the	literature	
 Identify	and	count	the	cost	of	treatment.	This	study	has	calculated	the	direct	costs	by	
schizophrenia	patients.	
 Establish	the	position	of	alternative	medicine	 in	Table	Cost	Effectiveness.	 	 It	 is	only	
cost	of	treatment,	not	cost	ratio.	
	
Pharmacotherapy	 has	 been	 given	 in	 this	 study	 was	 haloperidol	 and	 risperidol	
combined	 with	 chlorpromazine	 and	 trihexyphenidyl.	 Analysis	 of	 the	 results	 used	 the	
statistical	test	univariate	analysis	 followed	by	bivariate	analysis	Mann‐Whitney	 for	 the	
spread	of	abnormal	data.	
	
3. Result	and	Discussion	
	
3.1	Subjects	Characteristics	
 
Our	findings	showed	that	the	age	of	this	research	subjects	were	the	age	group	20‐
39	 years	 (20%),	 30‐39	 years	 (42.5%),	 40‐49	 years	 (27.5%),	 and	 the	 least	 is	 the	 age	
group	 >50	 year	 (10.0%).	 These	 results	 are	 consistent	 with	 the	 results	 of	 research	
conducted	by	Fahlian	Vishnu	(2011)	which	states	that	the	prevalence	of	schizophrenia	
patients	aged	greater	incidence	in	young	adults	compared	with	old	age.	This	is	because	
the	 age	 of	 30‐39	 years	 are	 productive	 age	 who	 tend	 to	 get	 into	 trouble‐complex	
problems,	including	problems	with	close	friends,	co‐workers,	work	too	hard,	economic,	
and	family	problems.	
	
The	 research	 subject	 has	 been	 divided	 into	 2	 groups,	 there	 are	 Haloperidol	
combination	 therapy	 and	 Risperidone	 combination	 therapy.	 Measurement	 of	 pre‐test	
PANSS‐EC	 scores	 show	 that	 there	 was	 no	 significant	 difference	 in	 the	 two	 treatment	
groups	(p	=	0.155)	(Table	1).	It	means	that	both	groups	have	equal	treatment	at	the	time	
of	 initial	 therapy	 before	 treatment	 with	 the	 Haloperidol	 combination	 or	 Risperidone	
combination.	
	
Table	1.	Analysis	of	Pre‐test	PANSS‐EC	Scores	between	Haloperidol	Combination	Therapy	
with	Risperidone	Combination	Therapy	
Drugs	 n Mean	PANSS‐EC	Score	 Sig.	(2‐tailed)	
Pre‐test									Risperidon	group
																								Haloperidol	group		
																								Total	
20
20	
40	
18.18
22.83	
0.155	
	 	 The	results	of	this	study	have	been	shown	that	patients	with	acute	phase	occurred	
in	 the	 first	 7	 days,	 between	 1	 days	 until	 3	 days	 (Table	 2).	 This	 is	 consistent	with	 the	
American	 Psychiatric	 Association	 (APA),	 which	 states	 schizophrenia	 disease	 course	
consists	 of	 three	 phases:	 the	 acute	 phase,	 the	 stabilization	 phase	 and	 stable	 phase	
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(Reverger,	 2012).	 In	 the	 acute	 phase,	 a	 therapeutic	 target	 is	 reduce	 or	 eliminate	 the	
psychotic	 symptoms	 and	 improve	 the	 functioning	 of	 the	 patient's	 normal	 that	 usually	
occurs	during	the	first	7	days	(Dipiro	et	al,	2009).	
	
Table	2.	The	Duration	Distribution	of	Acute	Phase	in	The	Research	Subject		
Duration	Acute	Phase	
(Day)	 			Frequency	
Percent	
(%)	
Cumulative	
Percent	(%)	
1	
2	
3	
8	
Total	
23	
9	
7	
1	
40	
57.5	
22.5	
17.5	
2.5	
100.0	
57.5	
80.0	
97.5	
100.0	
	
3.2.	 The	 Comparison	 of	 Effectiveness	 between	 Haloperidol	 Combination	 Therapy	 with	
Risperidone	Combination	Therapy	based	on	PANSS‐EC	Score	
	
Our	results	have	shown	that	the	PANSS‐EC	scores	 in	both	treatment	groups	there	was	
no	significant	difference	(p=0.711)	(Table	3).	The	results	of	this	study	do	not	correspond	
with	 the	 results	 of	 research	 conducted	 by	 Leucht	 et	 al	 (2009),	where	 the	 results	 of	 a	
meta‐analysis	 that	 has	 been	 conducted	 shows	 that	 53%	 of	 patients	 who	 received	
risperidone	doses	above	6	mg	per	day	meets	the	criteria	of	 improvement	compared	to	
40%	of	 patients	who	 received	 conventional	 antipsychotics	 (p<0.001).	 Treatment	with	
risperidone	 also	 results	 in	 a	 25%	 better	 against	 positive	 symptoms	 and	 60%	 better	
against	the	negative	symptoms	compared	with	conventional	antipsychotics.	The	results	
of	 the	 meta‐analysis	 showed	 that	 risperidone	 meet	 the	 criteria	 of	 positive	 symptom	
improvement	is	better	than	the	conventional	antipsychotics	(p	<0.001).	
	
Tabel	3.	Analysis	of	Post‐test	PANSS‐EC	Scores	between	Haloperidol	Combination	Therapy		
with	Risperidone	Combination	Therapy	
	
Drugs	 n Mean PANSS‐EC	Score Sig.	(2‐tailed)	
Post‐test			Risperidon	group					
					Haloperidol	group	
					Total			
20
20	
40	
21.18
19.83	
0.711	
The	reason	of	our	result	may	be	because	this	study	used	the	combination	therapy,	
not	 a	 single	 therapy.	 In	 addition,	both	 types	of	 antipsychotics	 are	equally	 effective	 for	
treating	 the	 positive	 symptoms	 in	 schizophrenic	 patients,	 although	 in	 the	 risperidone	
(an	 atypical	 antipsychotic)	 actually	 has	 a	 high	 effectiveness	 for	 treating	 positive	
symptoms	and	negative	symptoms	(Harvey	et	al,	2016).	Both	types	of	antipsychotics	are	
also	effective	in	blocking	the	dopamine	receptor	type	2	(D2)	that	is	specific	mesolimbic	
dopamine	 pathway.	 Blocks	 the	 action	 of	 dopamine	 receptor	 type	 2	 has	 the	 effect	 of	
lowering	 the	hyperactivity	 in	 the	path	 that	 led	 to	 the	 emergence	of	psychotic	positive	
symptoms	(Stahl,	2003).	
	
Positive	symptoms	more	prominent	that	the	dopamine	receptor	type	2	which	will	
play	 a	 role	 in	 the	 acute	 phase,	 so	 that	 the	 positive	 symptoms	 is	 needed	 D2	 receptor	
blockade.	The	combination	of	Haloperidol	and	Chlorpromazine	is	suitable	for	both	work	
the	same	way	that	blocks	the	D2	receptor,	whereas	risperidone	in	addition	to	blocking	
the	D2	receptor	also	block	the	receptor	5‐HT2	(Stahl,	2003).	It	may	make	both	types	of	
therapy	are	equally	effective	for	the	treatment	of	schizophrenia,	because	most	patients	
in	this	study	come	with	positive	symptoms	dominan	in	the	acute	phase,	and	in	this	study	
the	researchers	did	not	differentiate	patients	with	schizophrenia	acute	phase	based	on	
the	initial	symptoms	appear.	
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3.3.	The	Comparison	of		Cost‐Effectiveness	between	Haloperidol	Combination	Therapy	with	
Risperidone	Combination	Therapy		
	
The	 results	 of	 cost‐effectiveness	 comparison	 between	 haloperidol	 combination	
therapy	 with	 risperidone	 combination	 therapy	 have	 been	 conducted	 showing	
haloperidol	 combination	 therapy	 more	 cost‐effective	 than	 risperidone	 combination	
therapy	(table	4).	
	
Table	4.	Cost‐effectiveness	Comparison	between	Haloperidol	Combination	Therapy	with		
Risperidone	Combination	Therapy	
Cost	 Risperidon	Therapy	
Haloperidol		
Therapy	 Sig.	
Mean	 Rp	31.191,40	 Rp	11.186,95	 0.010	
Maximum	 Rp	7.598,00	 Rp	3.223,00	 	
Minimum	 Rp	139.560,00	 Rp	18.995,00	 	
	
Based	 on	 statistical	 analysis	 Mann‐Whitney	 test	 according	 to	 table	 4	 showed	 p	
value=0,010,	 it	means	 there	 is	 a	 significant	difference	between	 the	cost	of	haloperidol	
combination	 therapy	with	 risperidone	combination	 therapy.	When	compared	with	 the	
effectiveness	 of	 the	 therapy	 according	 to	 the	 score	 of	 the	 PANSS‐EC	 in	 this	 study,	 the	
effectiveness	 of	 Haloperidol	 combination	 therapy	 was	 same	 with	 risperidone	
combination	 therapy,	 so	 if	 the	 analysis	 is	 done	 using	 a	 table	 of	 alternative	 cost‐
effectiveness	 (Table	 5)	 obtained	 the	 results	 of	 the	 cost‐effectiveness	 of	 Haloperidol	
combination	therapy	more	lower	cost	than	Risperidon	combination	therapy.	
	
							Table	1.	Table	Cost‐Effectiveness	Analysis		
	 Low	Cost	 Same	Cost	 High	Cost	
Low	effectivity	
	
A B C	
Same	effectifity	
D	
Haloperidol	combination	
to	Risperidon	
combination	
E	 F	
Risperidon	combination	
to	Haloperidol	
combination	
High	effectivity	 G H I	
	
Based	 on	 Table	 5,	 where	 the	 cost‐effectiveness	 of	 the	 Risperidone	 combination	
therapy	compare	with	Haloperidol	combination	therapy	is	in	group	F,	so	no	need	to	use	
RIEB	 calculation.	 The	 layout	 of	 the	 cost‐effectiveness	 of	 the	 combination	 therapy	
Haloperidol	 against	 risperidone	 combination	 therapy	 is	 in	 group	 D,	 so	 that	 the	 cost‐
effectiveness	of	Haloperidol	 combination	 therapy	better	 than	 risperidone	 combination	
therapy.	
	
4. Conclusion	
	
This	 study	 showed	 that	 there	 was	 no	 difference	 of	 effectiveness	 when	 using	
haloperidol	combination	or	risperidone	combination	in	the	acute	phase	of	schizophrenia	
patients	 based	 on	 PANSS	 –	 EC,	 but	 the	 results	 of	 cost‐effectiveness	 analysis	 showed	
haloperidol	 combination	 therapy	 more	 cost‐effective	 than	 risperidone	 combination	
therapy	on	the	acute	phase	of	schizophrenia	patients.	
	
In	 this	 study	 has	 not	 been	 able	 to	 analyze	 the	 other	 factors	 that	 also	 affect	 the	
prognosis	 of	 the	 treatment	 of	 patients	 with	 schizophrenia	 as	 the	 onset	 of	 disease,	
chronicity,	precipitating	factors,	heredity,	social,	economic,	and	type	of	schizophrenia,	so	
more	research	is	needed.	
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